Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 929 | 16.16 |
09:38 ET | 300 | 16.22 |
09:43 ET | 100 | 16.19 |
09:50 ET | 300 | 16.215 |
09:52 ET | 100 | 16.215 |
09:54 ET | 100 | 16.21 |
10:03 ET | 100 | 16.2075 |
10:08 ET | 748 | 16.25 |
10:10 ET | 400 | 16.28 |
10:12 ET | 723 | 16.285 |
10:14 ET | 200 | 16.3275 |
10:15 ET | 452 | 16.315 |
10:24 ET | 3831 | 16.2 |
10:26 ET | 100 | 16.24 |
10:32 ET | 599 | 16.265 |
10:39 ET | 4510 | 16.24 |
10:57 ET | 2500 | 16.41 |
11:09 ET | 100 | 16.37 |
11:11 ET | 200 | 16.33 |
11:13 ET | 100 | 16.325 |
11:24 ET | 100 | 16.34 |
11:27 ET | 831 | 16.33 |
11:29 ET | 200 | 16.33 |
11:31 ET | 100 | 16.305 |
11:36 ET | 1736 | 16.4 |
11:42 ET | 200 | 16.4075 |
11:49 ET | 100 | 16.49 |
11:51 ET | 430 | 16.485 |
11:54 ET | 1250 | 16.48 |
11:58 ET | 100 | 16.46 |
12:02 ET | 892 | 16.435 |
12:05 ET | 200 | 16.405 |
12:07 ET | 100 | 16.425 |
12:14 ET | 510 | 16.325 |
12:18 ET | 100 | 16.39 |
12:20 ET | 300 | 16.35 |
12:23 ET | 2100 | 16.425 |
12:25 ET | 952 | 16.43 |
12:27 ET | 2947 | 16.49 |
12:30 ET | 100 | 16.46 |
12:32 ET | 700 | 16.445 |
12:34 ET | 100 | 16.425 |
12:39 ET | 100 | 16.43 |
12:41 ET | 100 | 16.41 |
12:43 ET | 100 | 16.44 |
12:45 ET | 200 | 16.425 |
12:48 ET | 1413 | 16.465 |
12:50 ET | 1013 | 16.47 |
12:52 ET | 500 | 16.51 |
12:54 ET | 100 | 16.495 |
12:56 ET | 100 | 16.48 |
01:03 ET | 100 | 16.5 |
01:06 ET | 428 | 16.53 |
01:08 ET | 400 | 16.56 |
01:10 ET | 100 | 16.56 |
01:12 ET | 400 | 16.55 |
01:14 ET | 100 | 16.56 |
01:17 ET | 806 | 16.58 |
01:21 ET | 600 | 16.555 |
01:26 ET | 400 | 16.5975 |
01:30 ET | 300 | 16.59 |
01:32 ET | 100 | 16.63 |
01:39 ET | 200 | 16.64 |
01:42 ET | 100 | 16.645 |
01:44 ET | 100 | 16.655 |
01:48 ET | 2129 | 16.6302 |
01:50 ET | 100 | 16.6 |
01:53 ET | 200 | 16.67 |
01:55 ET | 209 | 16.64 |
01:57 ET | 400 | 16.625 |
02:02 ET | 1100 | 16.62 |
02:04 ET | 100 | 16.62 |
02:06 ET | 724 | 16.535 |
02:08 ET | 200 | 16.535 |
02:18 ET | 200 | 16.55 |
02:22 ET | 954 | 16.445 |
02:26 ET | 100 | 16.43 |
02:33 ET | 100 | 16.46 |
02:36 ET | 2321 | 16.445 |
02:38 ET | 100 | 16.44 |
02:44 ET | 100 | 16.47 |
02:47 ET | 2118 | 16.53 |
02:49 ET | 100 | 16.535 |
02:51 ET | 8165 | 16.535 |
02:54 ET | 400 | 16.45 |
02:56 ET | 500 | 16.5 |
02:58 ET | 100 | 16.53 |
03:00 ET | 200 | 16.47 |
03:02 ET | 1650 | 16.565 |
03:03 ET | 315 | 16.62 |
03:07 ET | 515 | 16.64 |
03:09 ET | 706 | 16.7 |
03:12 ET | 210 | 16.695 |
03:16 ET | 2277 | 16.68 |
03:18 ET | 350 | 16.675 |
03:21 ET | 925 | 16.75 |
03:23 ET | 1009 | 16.74 |
03:25 ET | 100 | 16.77 |
03:30 ET | 100 | 16.77 |
03:34 ET | 100 | 16.78 |
03:38 ET | 100 | 16.83 |
03:39 ET | 310 | 16.79 |
03:41 ET | 200 | 16.8 |
03:43 ET | 100 | 16.8 |
03:45 ET | 300 | 16.82 |
03:48 ET | 300 | 16.87 |
03:50 ET | 864 | 16.85 |
03:52 ET | 1100 | 16.87 |
03:54 ET | 700 | 16.87 |
03:56 ET | 352 | 16.87 |
03:57 ET | 2433 | 16.86 |
03:59 ET | 16851 | 16.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 590.8M | -6.0x | --- |
Olema Pharmaceuticals Inc | 596.8M | -5.3x | --- |
Replimune Group Inc | 544.1M | -2.5x | --- |
PureTech Health PLC | 572.8M | -9.3x | --- |
Mineralys Therapeutics Inc | 617.1M | -5.7x | --- |
Alumis Inc | 593.6M | -3.5x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $590.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -6.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.